当前位置: 首页 >> 检索结果
共有 5672 条符合本次的查询结果, 用时 6.4774299 秒

61. Cardiogenic shock.

作者: Enzo Lüsebrink.;Leonhard Binzenhöfer.;Marianna Adamo.;Roberto Lorusso.;Alexandre Mebazaa.;David A Morrow.;Susanna Price.;Jacob C Jentzer.;Daniel Brodie.;Alain Combes.;Holger Thiele.
来源: Lancet. 2024年404卷10466期2006-2020页
Cardiogenic shock is a complex syndrome defined by systemic hypoperfusion and inadequate cardiac output arising from a wide array of underlying causes. Although the understanding of cardiogenic shock epidemiology, specific subphenotypes, haemodynamics, and cardiogenic shock severity staging has evolved, few therapeutic interventions have shown survival benefit. Results from seminal randomised controlled trials support early revascularisation of the culprit vessel in infarct-related cardiogenic shock and provide evidence of improved survival with the use of temporary circulatory support in selected patients. However, numerous questions remain unanswered, including optimal pharmacotherapy regimens, the role of mechanical circulatory support devices, management of secondary organ dysfunction, and best supportive care. This Review summarises current definitions, pathophysiological principles, and management approaches in cardiogenic shock, and highlights key knowledge gaps to advance individualised shock therapy and the evidence-based ethical use of modern technology and resources in cardiogenic shock.

62. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants.

作者: .
来源: Lancet. 2024年404卷10467期2077-2093页
Diabetes can be detected at the primary health-care level, and effective treatments lower the risk of complications. There are insufficient data on the coverage of treatment for diabetes and how it has changed. We estimated trends from 1990 to 2022 in diabetes prevalence and treatment for 200 countries and territories.

63. Evaluating the benefits of the early use of GLP-1 receptor agonists.

作者: Peter-James H Zushin.;Joseph C Wu.
来源: Lancet. 2025年405卷10474期181-183页

64. Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan.

作者: Takeshi Soma.;Yoshinori Oie.;Hiroshi Takayanagi.;Shoko Matsubara.;Tomomi Yamada.;Masaki Nomura.;Yu Yoshinaga.;Kazuichi Maruyama.;Atsushi Watanabe.;Kayo Takashima.;Zaixing Mao.;Andrew J Quantock.;Ryuhei Hayashi.;Kohji Nishida.
来源: Lancet. 2024年404卷10466期1929-1939页
The loss of corneal epithelial stem cells from the limbus at the edge of the cornea has severe consequences for vision, with the pathological manifestations of a limbal stem-cell deficiency (LSCD) difficult to treat. Here, to the best of our knowledge, we report the world's first use of corneal epithelial cell sheets derived from human induced pluripotent stem cells (iPSCs) to treat LSCD.

65. A history of hydrotherapy and mental health.

作者: Matthew Smith.
来源: Lancet. 2024年404卷10465期1804-1805页

66. Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.

作者: .
来源: Lancet. 2024年404卷10466期1955-1988页
Stillbirth is a devastating and often avoidable adverse pregnancy outcome. Monitoring stillbirth levels and trends-in a comprehensive manner that leaves no one uncounted-is imperative for continuing progress in pregnancy loss reduction. This analysis, completed as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, methodically accounted for different stillbirth definitions with the aim of comprehensively estimating all stillbirths at 20 weeks or longer for 204 countries and territories from 1990 to 2021.

67. Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial.

作者: David J Werring.;Hakim-Moulay Dehbi.;Norin Ahmed.;Liz Arram.;Jonathan G Best.;Maryam Balogun.;Kate Bennett.;Ekaterina Bordea.;Emilia Caverly.;Marisa Chau.;Hannah Cohen.;Mairead Cullen.;Caroline J Doré.;Stefan T Engelter.;Robert Fenner.;Gary A Ford.;Aneet Gill.;Rachael Hunter.;Martin James.;Archana Jayanthi.;Gregory Y H Lip.;Sue Massingham.;Macey L Murray.;Iwona Mazurczak.;Philip S Nash.;Amalia Ndoutoumou.;Bo Norrving.;Hannah Sims.;Nikola Sprigg.;Tishok Vanniyasingam.;Nick Freemantle.; .
来源: Lancet. 2024年
The optimal timing of anticoagulation for patients with acute ischaemic stoke with atrial fibrillation is uncertain. We investigated the efficacy and safety of early compared with delayed initiation of direct oral anticoagulants (DOACs) in patients with acute ischaemic stroke associated with atrial fibrillation.

68. The 2024 report of the Lancet Countdown on health and climate change: facing record-breaking threats from delayed action.

作者: Marina Romanello.;Maria Walawender.;Shih-Che Hsu.;Annalyse Moskeland.;Yasna Palmeiro-Silva.;Daniel Scamman.;Zakari Ali.;Nadia Ameli.;Denitsa Angelova.;Sonja Ayeb-Karlsson.;Sara Basart.;Jessica Beagley.;Paul J Beggs.;Luciana Blanco-Villafuerte.;Wenjia Cai.;Max Callaghan.;Diarmid Campbell-Lendrum.;Jonathan D Chambers.;Victoria Chicmana-Zapata.;Lingzhi Chu.;Troy J Cross.;Kim R van Daalen.;Carole Dalin.;Niheer Dasandi.;Shouro Dasgupta.;Michael Davies.;Robert Dubrow.;Matthew J Eckelman.;James D Ford.;Chris Freyberg.;Olga Gasparyan.;Georgiana Gordon-Strachan.;Michael Grubb.;Samuel H Gunther.;Ian Hamilton.;Yun Hang.;Risto Hänninen.;Stella Hartinger.;Kehan He.;Julian Heidecke.;Jeremy J Hess.;Louis Jamart.;Slava Jankin.;Harshavardhan Jatkar.;Ollie Jay.;Ilan Kelman.;Harry Kennard.;Gregor Kiesewetter.;Patrick Kinney.;Dominic Kniveton.;Rostislav Kouznetsov.;Pete Lampard.;Jason K W Lee.;Bruno Lemke.;Bo Li.;Yang Liu.;Zhao Liu.;Alba Llabrés-Brustenga.;Melissa Lott.;Rachel Lowe.;Jaime Martinez-Urtaza.;Mark Maslin.;Lucy McAllister.;Celia McMichael.;Zhifu Mi.;James Milner.;Kelton Minor.;Jan Minx.;Nahid Mohajeri.;Natalie C Momen.;Maziar Moradi-Lakeh.;Karyn Morrisey.;Simon Munzert.;Kris A Murray.;Nick Obradovich.;Megan B O'Hare.;Camile Oliveira.;Tadj Oreszczyn.;Matthias Otto.;Fereidoon Owfi.;Olivia L Pearman.;Frank Pega.;Andrew J Perishing.;Ana-Catarina Pinho-Gomes.;Jamie Ponmattam.;Mahnaz Rabbaniha.;Jamie Rickman.;Elizabeth Robinson.;Joacim Rocklöv.;David Rojas-Rueda.;Renee N Salas.;Jan C Semenza.;Jodi D Sherman.;Joy Shumake-Guillemot.;Pratik Singh.;Henrik Sjödin.;Jessica Slater.;Mikhail Sofiev.;Cecilia Sorensen.;Marco Springmann.;Zélie Stalhandske.;Jennifer D Stowell.;Meisam Tabatabaei.;Jonathon Taylor.;Daniel Tong.;Cathryn Tonne.;Marina Treskova.;Joaquin A Trinanes.;Andreas Uppstu.;Fabian Wagner.;Laura Warnecke.;Hannah Whitcombe.;Peng Xian.;Carol Zavaleta-Cortijo.;Chi Zhang.;Ran Zhang.;Shihui Zhang.;Ying Zhang.;Qiao Zhu.;Peng Gong.;Hugh Montgomery.;Anthony Costello.
来源: Lancet. 2024年404卷10465期1847-1896页
Despite the initial hope inspired by the 2015 Paris Agreement, the world is now dangerously close to breaching its target of limiting global multiyear mean heating to 1·5°C. Annual mean surface temperature reached a record high of 1·45°C above the pre-industrial baseline in 2023, and new temperature highs were recorded throughout 2024. The resulting climatic extremes are increasingly claiming lives and livelihoods worldwide. The Lancet Countdown: tracking progress on health and climate change was established the same year the Paris Agreement entered into force, to monitor the health impacts and opportunities of the world’s response to this landmark agreement. Supported through strategic core funding from Wellcome, the collaboration brings together over 300 multidisciplinary researchers and health professionals from around the world to take stock annually of the evolving links between health and climate change at global, regional, and national levels. The 2024 report of the Lancet Countdown, building on the expertise of 122 leading researchers from UN agencies and academic institutions worldwide, reveals the most concerning findings yet in the collaboration’s 8 years of monitoring.

69. Tranexamic acid for postpartum bleeding: a systematic review and individual patient data meta-analysis of randomised controlled trials.

作者: Katharine Ker.;Loïc Sentilhes.;Haleema Shakur-Still.;Hugo Madar.;Catherine Deneux-Tharaux.;George Saade.;Luis D Pacheco.;François-Xavier Ageron.;Raoul Mansukhani.;Eni Balogun.;Amy Brenner.;Danielle Prowse.;Monica Arribas.;Homa Ahmadzia.;Rizwana Chaudhri.;Oladapo Olayemi.;Ian Roberts.; .
来源: Lancet. 2024年404卷10463期1657-1667页
Tranexamic acid is a recommended treatment for women with a clinical diagnosis of postpartum haemorrhage, but whether it can prevent bleeding is unclear. We conducted a systematic review and individual patient data (IPD) meta-analysis of randomised controlled trials to assess the effects of tranexamic acid in women giving birth.

70. The effect of tranexamic acid on postpartum bleeding in women with moderate and severe anaemia (WOMAN-2): an international, randomised, double-blind, placebo-controlled trial.

作者: .
来源: Lancet. 2024年404卷10463期1645-1656页
Tranexamic acid, given within 3 h of birth, reduces bleeding deaths in women with postpartum haemorrhage. We examined whether giving tranexamic acid shortly after birth can prevent postpartum haemorrhage in women with moderate or severe anaemia.

71. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.

作者: Mary McCormack.;Gemma Eminowicz.;Dolores Gallardo.;Patricia Diez.;Laura Farrelly.;Christopher Kent.;Emma Hudson.;Miguel Panades.;Tony Mathew.;Anjana Anand.;Mojca Persic.;Jennifer Forrest.;Rajanee Bhana.;Nicholas Reed.;Anne Drake.;Madhavi Adusumalli.;Asima Mukhopadhyay.;Margaret King.;Karen Whitmarsh.;John McGrane.;Nicoletta Colombo.;Choi Mak.;Ranajit Mandal.;Rahul Roy Chowdhury.;Gabriela Alamilla-Garcia.;Adriana Chávez-Blanco.;Hilary Stobart.;Amanda Feeney.;Simran Vaja.;Anne-Marie Hacker.;Allan Hackshaw.;Jonathan Andrew Ledermann.; .
来源: Lancet. 2024年404卷10462期1525-1535页
Locally advanced cervical cancer is treated with chemoradiotherapy (standard of care), but many patients still relapse and die from metastatic disease. We investigated chemoradiotherapy with or without induction chemotherapy to determine whether induction chemotherapy improves both progression-free survival and overall survival.

72. Efficacy of a culturally adapted, cognitive behavioural therapy-based intervention for postnatal depression in British south Asian women (ROSHNI-2): a multicentre, randomised controlled trial.

作者: Nusrat Husain.;Farah Lunat.;Karina Lovell.;Jahanara Miah.;Carolyn A Chew-Graham.;Penny Bee.;Ahmed Waqas.;Matthias Pierce.;Deepali Sharma.;Najia Atif.;Saadia Aseem.;Kamaldeep Bhui.;Peter Bower.;Traolach Brugha.;Nasim Chaudhry.;Akbar Ullah.;Linda Davies.;Nadeem Gire.;Joe Kai.;Jillian Morrison.;Naeem Mohmed.;Shanaya Rathod.;Najma Siddiqi.;Siham Sikander.;Waquas Waheed.;Ilyas Mirza.;Christopher Williams.;Nosheen Zaidi.;Richard Emsley.;Atif Rahman.;Richard Morriss.
来源: Lancet. 2024年404卷10461期1430-1443页
Postnatal depression necessitates timely and effective interventions to mitigate adverse maternal and child outcomes in the short term and over the life course. British south Asian women with depression are often underserved and undertreated due to stigma, language barriers, and cultural barriers. This trial aimed to test the clinical efficacy of a culturally adapted, group cognitive behavioural therapy (CBT)-based intervention, the Positive Health Programme (PHP), delivered by non-specialist health workers for postnatal depression in British south Asian women.

73. 5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.

作者: Firdausi Qadri.;Farhana Khanam.;Yiyuan Zhang.;Prasanta Kumar Biswas.;Merryn Voysey.;Yama F Mujadidi.;Sarah Kelly.;Amirul Islam Bhuiyan.;Nazmul Hasan Rajib.;Ismail Hossen.;Nazia Rahman.;Sadia Islam.;Virginia E Pitzer.;Young Chan Kim.;John D Clemens.;Andrew J Pollard.;Xinxue Liu.
来源: Lancet. 2024年404卷10461期1419-1429页
WHO currently recommends a single dose of typhoid conjugate vaccine (TCV) in high-burden countries based on 2-year vaccine efficacy data from large randomised controlled trials. Given the decay of immunogenicity, the protection beyond 2 years is unknown. We therefore extended the follow-up of the TyVAC trial in Bangladesh to assess waning of vaccine protection to 5 years after vaccination.

74. Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.

作者: .
来源: Lancet. 2024年404卷10461期1407-1418页
Distant recurrence in women with oestrogen receptor-positive early breast cancer persists at a constant rate for more than 20 years after diagnosis, with little equivalent data for oestrogen receptor-negative breast cancer. Using the database of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) we investigated rates of distant breast-cancer recurrence in oestrogen receptor-positive and oestrogen receptor-negative tumours and trends in outcomes over time.

75. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.

作者: .
来源: Lancet. 2024年404卷10459期1199-1226页
Antimicrobial resistance (AMR) poses an important global health challenge in the 21st century. A previous study has quantified the global and regional burden of AMR for 2019, followed with additional publications that provided more detailed estimates for several WHO regions by country. To date, there have been no studies that produce comprehensive estimates of AMR burden across locations that encompass historical trends and future forecasts.

76. Antimicrobial resistance in carceral settings.

作者: Samuel Wilk.;Jacinda C Abdul-Mutakabbir.;Shira Doron.;Christina Yen.;Justin Berk.;Alysse Wurcel.
来源: Lancet. 2024年404卷10457期1015-1016页

77. Antimicrobial resistance at a crossroads: the cost of inaction.

作者: Michael Craig.;Daniel Jernigan.;Kayla Laserson.;Stefanie McBride.;Jessica Fairbanks.;Dawn Sievert.;Paige A Armstrong.;Heather Ewing Ogle.;Howard Zucker.
来源: Lancet. 2024年404卷10458期1083-1085页

78. Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies.

作者: Natalie I Mazur.;Mauricio T Caballero.;Marta C Nunes.
来源: Lancet. 2024年404卷10458期1143-1156页
The global burden of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in young children is high. The RSV prevention strategies approved in 2023 will be essential to lowering the global disease burden. In this Series paper, we describe clinical presentation, burden of disease, hospital management, emerging therapies, and targeted prevention focusing on developments and groundbreaking publications for RSV. We conducted a systematic search for literature published in the past 15 years and used a non-systematic approach to analyse the results, prioritising important papers and the most recent reviews per subtopic. Annually, 33 million episodes of RSV LRTI occur in children younger than 5 years, resulting in 3·6 million hospitalisations and 118 200 deaths. RSV LRTI is a clinical diagnosis but a clinical case definition and universal clinical tool to predict severe disease are non-existent. The advent of molecular point-of-care testing allows rapid and accurate confirmation of RSV infection and could reduce antibiotic use. There is no evidence-based treatment of RSV, only supportive care. Despite widespread use, evidence for high-flow nasal cannula (HFNC) therapy is insufficient and increased paediatric intensive care admissions and intubation indicate the need to remove HFNC therapy from standard care. RSV is now a vaccine-preventable disease in young children with a market-approved long-acting monoclonal antibody and a maternal vaccine targeting the RSV prefusion protein. To have a high impact on life-threatening RSV infection, infants at high risk, especially in low-income and middle-income countries, should be prioritised as an interim strategy towards universal immunisation. The implementation of RSV preventive strategies will clarify the full burden of RSV infection. Vaccine probe studies can address existing knowledge gaps including the effect of RSV prevention on transmission dynamics, antibiotic misuse, the respiratory microbiome composition, and long-term sequalae.

79. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.

作者: Pardeep S Jhund.;Atefeh Talebi.;Alasdair D Henderson.;Brian L Claggett.;Muthiah Vaduganathan.;Akshay S Desai.;Carolyn S P Lam.;Bertram Pitt.;Michele Senni.;Sanjiv J Shah.;Adriaan A Voors.;Faiez Zannad.;Scott D Solomon.;John J V McMurray.
来源: Lancet. 2024年404卷10458期1119-1131页
Mineralocorticoid receptor antagonists (MRAs) reduce hospitalisations and death in patients with heart failure and reduced ejection fraction (HFrEF), but the benefit in patients with heart failure and mildly reduced ejection fraction (HFmrEF) or heart failure and preserved ejection fraction (HFpEF) is unclear. We evaluated the effect of MRAs in four trials that enrolled patients with heart failure across the range of ejection fraction.

80. General and abdominal adiposity and hypertension in eight world regions: a pooled analysis of 837 population-based studies with 7·5 million participants.

作者: .
来源: Lancet. 2024年404卷10455期851-863页
Adiposity can be measured using BMI (which is based on weight and height) as well as indices of abdominal adiposity. We examined the association between BMI and waist-to-height ratio (WHtR) within and across populations of different world regions and quantified how well these two metrics discriminate between people with and without hypertension.
共有 5672 条符合本次的查询结果, 用时 6.4774299 秒